Improved Assessment of Coronary Artery Disease in Obese Subjects with Flurpiridaz-18F PET Myocardial Perfusion Imaging: A Prespecified Subgroup Analysis of the AURORA Phase 3 Study

By afschroeder • May 14, 2026

Patel KK, Maddahi J, Agostini D, Bax JJ, Beanlands RSB, Berman D, Dorbala S, Heller GV, Knuuti JM, Pelletier-Galarneau M, Tamaki N, Thompson D, Somer EJ, Udelson JE, Bateman TM. Improved Assessment of Coronary Artery Disease in Obese Subjects with Flurpiridaz-¹⁸F PET Myocardial Perfusion Imaging: A Prespecified Subgroup Analysis of the AURORA Phase 3 Study. J Nucl Cardiol. 2026 May 12:102741. doi: 10.1016/j.nuclcard.2026.102741. Epub ahead of print. PMID: 42128226.

Tags: Cardiac PET, Cardiology/Epi, Cedars Sinai DoM, coronary artery disease, F-18 flurpiridaz, myocardial perfusion imaging, Obesity, Publications, radiotracers

Related Posts

Pregnancy damps thermoregulatory rhythms across timescales through neural estrogen signaling in mice

Cortes LR, Xiong L, Vree AR, Reis FMCV, Kim N, Feng B, Hansen MR, Rashid S, Sandoval NP, Lopez JI, He Y, Adhikari A, van[...]

MAGGIC and PREDICT-HF Models in the VICTOR Trial: Do Traditional Risk Scores Still Work in Well-Treated Ambulatory Patients with HFrEF?

Senni M, Butler J, Cyr D, Anstrom KJ, Barash I, Bonaca MP, Budoff M, Cho MC, Crespo-Leiro MG, Corda S, Ezekowitz J, Lam CSP, Lewis[...]

Artificial intelligence-derived splenic response in cardiac positron emission tomography is associated with major adverse cardiovascular events: a multi-site study

Ramirez G, Dharmavaram NL, Shanbhag A, Miller RJH, Kavanagh PB, Yi J, Lemley M, Builoff V, Marcinkiewicz A, Dey D, Hainer J, Wopperer S, Knight[...]